Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LSG plus Mazdutide for severe obesity (postoperative initiation at 3 months)
ChiCTR2600130221Phase 4Not yet recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Aug 2026
- Modality
- Hormonal Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mazdutide in obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiometabolic risk (CMR), sponsored by Fujian Provincial Hospital. Primary endpoint: Difference in Percentage Total Weight Loss (%TWL) Between Groups at Week 48. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
mazdutide
03
Conditions
obesitymetabolic dysfunction-associated steatotic liver disease (MASLD)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on ChiCTR2600130221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130221.